科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: Anti-nuclear antibodies (ANA) are suspected of having relevance to adverse reproductive events. Methods: This study aims to investigate the potential effect of ANA on IVF/ICSI outcome and the therapeutic role of prednisone plus low-dose aspirin (P + A) adjuvant treatment in ANA + patients. The first IVF/ICSI cycles without P + A of sixty-six ANA + women were enrolled as the ANA + group, and the 233 first IVF/ICSI cycles of matched ANA-women served as the ANA- group. The ANA + group was divided into the Titre < = 1: 320 subgroup and the Titre > 1: 320 subgroup. Twenty-one ANA + women with adverse outcomes in their first cycles (ANA + cycles without P + A) received P + A adjuvant treatment for three months before the second IVF/ICSI cycle (ANA + cycles with P + A). The clinical characteristics and the IVF/ICSI outcomes were compared, respectively, between 1) the ANA + group and the ANA-group, 2) the Titre < = 1: 320 subgroup and the Titre > 1: 320 subgroup, and 3) the ANA + cycles without P + A and the ANA + cycles with P + A. Results: No significant differences were observed between each of the two-group pairs in the clinical characteristics. The ANA + group exhibited significantly lower MII oocytes rate, normal fertilisation, pregnancy and implantation rates, as well as remarkably higher abnormal fertilisation and early miscarriage rates. The Titre < = 1: 320 subgroup's IVF/ICSI outcomes were as poor as those of the Titre > 1: 320 subgroup. After the P + A adjuvant treatment, the number of two pro-nuclei, perfect embryos and available embryos, and the implantation rate increased significantly. Conclusions: These observations suggest that ANA could exert a detrimental effect on IVF/ICSI outcome that might not be titre-dependent, and P + A adjuvant treatment could be useful for ANA + patients. This hypothesis should be verified in further prospective randomised studies.
